Cargando…
Continuous Infusion of High Doses of Cefepime in Intensive Care Unit: Assessment of Steady-State Plasma Level and Incidence on Neurotoxicity
Continuous infusion (CI) with high doses of cefepime is recommended in the empirical antimicrobial regimen of critically ill patients with suspected Gram-negative sepsis. This study aimed to determine factors associated with cefepime overdosing and the incidence of cefepime-induced neurotoxicity (CI...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9854724/ https://www.ncbi.nlm.nih.gov/pubmed/36671270 http://dx.doi.org/10.3390/antibiotics12010069 |
_version_ | 1784873192869855232 |
---|---|
author | Jean-Michel, Vanessa Homey, Corentin Devos, Patrick Delannoy, Pierre-Yves Boussekey, Nicolas Caulier, Thomas Leroy, Olivier Georges, Hugues |
author_facet | Jean-Michel, Vanessa Homey, Corentin Devos, Patrick Delannoy, Pierre-Yves Boussekey, Nicolas Caulier, Thomas Leroy, Olivier Georges, Hugues |
author_sort | Jean-Michel, Vanessa |
collection | PubMed |
description | Continuous infusion (CI) with high doses of cefepime is recommended in the empirical antimicrobial regimen of critically ill patients with suspected Gram-negative sepsis. This study aimed to determine factors associated with cefepime overdosing and the incidence of cefepime-induced neurotoxicity (CIN) in these patients. We performed a retrospective study including all patients receiving cefepime treatment between January 2019 and May 2022. The plasma level of cefepime defining overdosing was over 35 mg/L. Neurotoxicity was defined according to strict criteria and correlated with concomitant steady-state concentration of cefepime. Seventy-eight courses of cefepime treatment were analyzed. The mean cefepime plasma level at steady state was 59.8 ± 29.3 mg/L, and overdosing occurred in 80% of patients. Renal failure and a daily dose > 5 g were independently associated with overdosing. CIN was present in 30% of patients. In multivariate analysis, factors associated with CIN were chronic renal failure and a cefepime plasma concentration ≥ 60 mg/L. CIN was not associated with mortality. Overdosing is frequent in patients receiving high doses of cefepime by CI. Steady-state levels are higher than targeted therapeutic pharmacokinetic/pharmacodynamic objectives. The risk of CIN is important when the plasma concentration is ≥60 mg/L. |
format | Online Article Text |
id | pubmed-9854724 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-98547242023-01-21 Continuous Infusion of High Doses of Cefepime in Intensive Care Unit: Assessment of Steady-State Plasma Level and Incidence on Neurotoxicity Jean-Michel, Vanessa Homey, Corentin Devos, Patrick Delannoy, Pierre-Yves Boussekey, Nicolas Caulier, Thomas Leroy, Olivier Georges, Hugues Antibiotics (Basel) Review Continuous infusion (CI) with high doses of cefepime is recommended in the empirical antimicrobial regimen of critically ill patients with suspected Gram-negative sepsis. This study aimed to determine factors associated with cefepime overdosing and the incidence of cefepime-induced neurotoxicity (CIN) in these patients. We performed a retrospective study including all patients receiving cefepime treatment between January 2019 and May 2022. The plasma level of cefepime defining overdosing was over 35 mg/L. Neurotoxicity was defined according to strict criteria and correlated with concomitant steady-state concentration of cefepime. Seventy-eight courses of cefepime treatment were analyzed. The mean cefepime plasma level at steady state was 59.8 ± 29.3 mg/L, and overdosing occurred in 80% of patients. Renal failure and a daily dose > 5 g were independently associated with overdosing. CIN was present in 30% of patients. In multivariate analysis, factors associated with CIN were chronic renal failure and a cefepime plasma concentration ≥ 60 mg/L. CIN was not associated with mortality. Overdosing is frequent in patients receiving high doses of cefepime by CI. Steady-state levels are higher than targeted therapeutic pharmacokinetic/pharmacodynamic objectives. The risk of CIN is important when the plasma concentration is ≥60 mg/L. MDPI 2022-12-30 /pmc/articles/PMC9854724/ /pubmed/36671270 http://dx.doi.org/10.3390/antibiotics12010069 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Jean-Michel, Vanessa Homey, Corentin Devos, Patrick Delannoy, Pierre-Yves Boussekey, Nicolas Caulier, Thomas Leroy, Olivier Georges, Hugues Continuous Infusion of High Doses of Cefepime in Intensive Care Unit: Assessment of Steady-State Plasma Level and Incidence on Neurotoxicity |
title | Continuous Infusion of High Doses of Cefepime in Intensive Care Unit: Assessment of Steady-State Plasma Level and Incidence on Neurotoxicity |
title_full | Continuous Infusion of High Doses of Cefepime in Intensive Care Unit: Assessment of Steady-State Plasma Level and Incidence on Neurotoxicity |
title_fullStr | Continuous Infusion of High Doses of Cefepime in Intensive Care Unit: Assessment of Steady-State Plasma Level and Incidence on Neurotoxicity |
title_full_unstemmed | Continuous Infusion of High Doses of Cefepime in Intensive Care Unit: Assessment of Steady-State Plasma Level and Incidence on Neurotoxicity |
title_short | Continuous Infusion of High Doses of Cefepime in Intensive Care Unit: Assessment of Steady-State Plasma Level and Incidence on Neurotoxicity |
title_sort | continuous infusion of high doses of cefepime in intensive care unit: assessment of steady-state plasma level and incidence on neurotoxicity |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9854724/ https://www.ncbi.nlm.nih.gov/pubmed/36671270 http://dx.doi.org/10.3390/antibiotics12010069 |
work_keys_str_mv | AT jeanmichelvanessa continuousinfusionofhighdosesofcefepimeinintensivecareunitassessmentofsteadystateplasmalevelandincidenceonneurotoxicity AT homeycorentin continuousinfusionofhighdosesofcefepimeinintensivecareunitassessmentofsteadystateplasmalevelandincidenceonneurotoxicity AT devospatrick continuousinfusionofhighdosesofcefepimeinintensivecareunitassessmentofsteadystateplasmalevelandincidenceonneurotoxicity AT delannoypierreyves continuousinfusionofhighdosesofcefepimeinintensivecareunitassessmentofsteadystateplasmalevelandincidenceonneurotoxicity AT boussekeynicolas continuousinfusionofhighdosesofcefepimeinintensivecareunitassessmentofsteadystateplasmalevelandincidenceonneurotoxicity AT caulierthomas continuousinfusionofhighdosesofcefepimeinintensivecareunitassessmentofsteadystateplasmalevelandincidenceonneurotoxicity AT leroyolivier continuousinfusionofhighdosesofcefepimeinintensivecareunitassessmentofsteadystateplasmalevelandincidenceonneurotoxicity AT georgeshugues continuousinfusionofhighdosesofcefepimeinintensivecareunitassessmentofsteadystateplasmalevelandincidenceonneurotoxicity |